Silexion Therapeutics (SLXN) Competitors $1.77 -0.08 (-4.32%) As of 01/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends SLXN vs. CLDI, PMCB, BCLI, TSBX, BCDA, KLTO, ONVO, PALI, CERO, and EVAXShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Calidi Biotherapeutics (CLDI), PharmaCyte Biotech (PMCB), Brainstorm Cell Therapeutics (BCLI), Turnstone Biologics (TSBX), BioCardia (BCDA), Klotho Neurosciences (KLTO), Organovo (ONVO), Palisade Bio (PALI), CERo Therapeutics (CERO), and Evaxion Biotech A/S (EVAX). These companies are all part of the "biological products, except diagnostic" industry. Silexion Therapeutics vs. Calidi Biotherapeutics PharmaCyte Biotech Brainstorm Cell Therapeutics Turnstone Biologics BioCardia Klotho Neurosciences Organovo Palisade Bio CERo Therapeutics Evaxion Biotech A/S Silexion Therapeutics (NASDAQ:SLXN) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability. Which has more volatility and risk, SLXN or CLDI? Silexion Therapeutics has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Does the media refer more to SLXN or CLDI? In the previous week, Calidi Biotherapeutics had 10 more articles in the media than Silexion Therapeutics. MarketBeat recorded 12 mentions for Calidi Biotherapeutics and 2 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 1.14 beat Calidi Biotherapeutics' score of 0.06 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Calidi Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in SLXN or CLDI? Silexion Therapeutics received 1 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSilexion TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesCalidi BiotherapeuticsN/AN/A Do insiders and institutionals believe in SLXN or CLDI? 10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 33.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 24.3% of Calidi Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is SLXN or CLDI more profitable? Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -249.43% Calidi Biotherapeutics N/A N/A -344.45% Which has higher valuation and earnings, SLXN or CLDI? Silexion Therapeutics has higher earnings, but lower revenue than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A$260KN/AN/ACalidi Biotherapeutics$50K231.69-$29.22MN/AN/A Do analysts rate SLXN or CLDI? Silexion Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 408.47%. Calidi Biotherapeutics has a consensus target price of $16.67, suggesting a potential upside of 1,781.54%. Given Calidi Biotherapeutics' higher probable upside, analysts plainly believe Calidi Biotherapeutics is more favorable than Silexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCalidi Biotherapeutics beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84M$2.92B$5.25B$8.79BDividend YieldN/A1.94%5.07%4.00%P/E RatioN/A45.0288.0316.96Price / SalesN/A405.921,110.71123.60Price / Cash5.75182.3143.2137.77Price / Book-0.276.395.044.89Net Income$260,000.00-$41.49M$122.32M$228.40M7 Day Performance-8.76%-7.16%-2.88%-2.25%1 Month Performance-49.72%-6.46%-1.07%-0.42%1 Year PerformanceN/A-5.88%22.97%13.53% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$1.77-4.3%$9.00+408.5%N/A$2.84MN/A0.00N/APositive NewsCLDICalidi Biotherapeutics2.3767 of 5 stars$0.91-0.2%$16.67+1,724.9%N/A$11.94M$50,000.000.0038Gap UpPMCBPharmaCyte Biotech2.1336 of 5 stars$1.53+0.7%N/A-32.0%$11.75MN/A2.892Short Interest ↓Positive NewsBCLIBrainstorm Cell Therapeutics4.2332 of 5 stars$2.02-0.2%$30.00+1,388.8%-58.4%$11.49MN/A-0.4240Short Interest ↓Positive NewsGap UpTSBXTurnstone Biologics3.6944 of 5 stars$0.47-2.1%$2.13+352.1%-77.4%$10.87M$19.31M-0.1582News CoverageBCDABioCardia3.7833 of 5 stars$2.30+8.0%$25.00+987.0%-77.8%$10.54M$71,000.00-0.5540Short Interest ↓Positive NewsGap UpKLTOKlotho NeurosciencesN/A$0.47-5.5%N/AN/A$9.95MN/A0.00N/AONVOOrganovo1.7321 of 5 stars$0.36-9.9%N/A-66.6%$5.54M$103,000.00-0.3420Analyst ForecastShort Interest ↓Gap UpPALIPalisade Bio3.5005 of 5 stars$1.88-1.6%$23.00+1,123.4%-77.7%$5.20M$250,000.00-0.1310Short Interest ↓Positive NewsCEROCERo TherapeuticsN/A$3.26+10.1%N/AN/A$4.90MN/A0.008Stock SplitShort Interest ↓Positive NewsGap DownEVAXEvaxion Biotech A/S2.6312 of 5 stars$0.82-81.8%$55.00+6,607.3%-90.5%$4.81M$3.30M-2.8360Short Interest ↑News CoverageGap Down Related Companies and Tools Related Companies Calidi Biotherapeutics Alternatives PharmaCyte Biotech Alternatives Brainstorm Cell Therapeutics Alternatives Turnstone Biologics Alternatives BioCardia Alternatives Klotho Neurosciences Alternatives Organovo Alternatives Palisade Bio Alternatives CERo Therapeutics Alternatives Evaxion Biotech A/S Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLXN) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLXN Stock Alerts